Key Takeaways

  • ResMed's ASX-listed securities were down about 4.76% at $28.60 by around 11.04am AEST on Monday 13 July 2026, based on a 20-minute delayed snapshot; intraday levels can change through the session.
  • No fresh, company-specific announcement was identified in the available material at the time of writing; the ASX Health Care sector was down about 0.82%, one of the market's weaker segments on the morning.
  • ResMed's US-listed shares have been trading near 52-week lows, reported down about 14.5% in 2026 and roughly 29% below their August 2025 high, amid concerns about GLP-1 weight-loss drugs and Philips' return to the US market.
  • On 7 July 2026, ResMed announced a definitive agreement, entered 30 June, to sell its MatrixCare software business to Frazier Healthcare Partners for US$490 million, with proceeds earmarked substantially for capital returns.
  • Third-quarter FY2026 results, reported 30 April 2026, showed revenue up 11% to US$1.431 billion and non-GAAP EPS up 21% to US$2.86; full-year results for the year ended 30 June 2026 are the next major catalyst.

The Australian share market's Monday morning weakness on 13 July 2026 had several sources, but healthcare was prominent among them — and ResMed Inc. (ASX: RMD) was one of the sector's heaviest fallers. By around 11.04am AEST, ResMed's ASX-listed securities were trading at $28.60, down about 4.76%, according to market data delayed by roughly 20 minutes. As always with intraday snapshots taken early in the session, both price and percentage can shift before the close.

The Health Care sector index was down about 0.82% at a similar point — among the weaker sector readings on a morning when the S&P/ASX 200 slipped about 0.18% to around 8,789.80 after opening higher. With heavyweight healthcare names under pressure, the sector acted as one of the larger drags on the benchmark, even as energy stocks rallied on a jump in oil prices following weekend US strikes on Iran and Tehran's declaration that the Strait of Hormuz was closed.

ResMed's fall of nearly 5% was several times deeper than its sector's, which invites the obvious question: was there ResMed-specific news? On the available evidence, no — but the company has hardly been short of newsflow lately, and the context of a stock already trading near its lows helps explain the magnitude.

What Happened to the ResMed Share Price

At the mid-morning snapshot, ResMed's ASX securities — CHESS Depositary Interests (CDIs) over the San Diego-based company's NYSE-listed shares — were quoted at $28.60, down about 4.76%. Because the primary listing is in New York, ASX trading in ResMed often reflects moves in the US shares from Friday's Wall Street session, currency shifts and local sentiment in combination. The Australian dollar was weaker on Monday morning, trading near US69.31 cents, down about 0.16%.

The broader trajectory matters more than one morning. ResMed's US-listed stock has been languishing near 52-week lows, reported in market coverage at around US$209 — down approximately 14.5% since the beginning of 2026 and roughly 28.8% below its 52-week high of US$293.73 set in August 2025. That derating has occurred despite the company reporting double-digit revenue and earnings growth, a divergence that has itself become a subject of debate among analysts, with some arguing the market is overpricing structural threats and others seeing the caution as warranted.

Monday's ASX fall, then, is best read as a continuation — amplified by a soft local session — of a pressure that has been building on the stock for months.

ResMed: A Global Leader in Sleep and Breathing Health

ResMed is one of the largest medical device companies listed on the ASX, though its corporate home is San Diego, California, and its primary listing is the New York Stock Exchange, with CDIs traded in Australia. Founded on Australian research into obstructive sleep apnoea (OSA), the company has grown into the global leader in devices that treat sleep-disordered breathing — principally continuous positive airway pressure (CPAP) machines, masks and accessories — alongside ventilation products for chronic respiratory disease.

The company's strategy in recent years has paired hardware with software and data. More than a billion nights of sleep data flow through its connected devices and digital health platforms, supporting adherence, remote monitoring and reimbursement. Its Residential Care Software arm has served out-of-hospital care settings, although that portfolio is now being reshaped — most notably through the agreed sale of MatrixCare, its US-focused software business for skilled nursing, senior living and home health providers.

ResMed's investment narrative for 2026 has been defined by a tug-of-war. On one side: consistent double-digit earnings growth, expanding margins and a huge, underpenetrated global pool of undiagnosed sleep apnoea sufferers. On the other: fear that GLP-1 obesity drugs will shrink the future patient funnel, and that a returning Philips will contest share. Chief executive Mick Farrell has publicly taken the opposite view on GLP-1s, describing them as "a once-in-a-generation demand gen opportunity" and citing company data showing patients prescribed both a GLP-1 and positive airway pressure therapy are around 11% more likely to start PAP treatment than those prescribed PAP alone.

Operations and Product Portfolio

ResMed's operations span more than 140 countries, organised around two reported revenue streams. The larger, Sleep and Breathing Health, covers CPAP and bilevel devices, masks and accessories, plus ventilators — generating US$1.26 billion in the March 2026 quarter, up 11% year on year. The smaller, Residential Care Software, produced US$170.9 million in the same quarter, up 6%.

The company's device ecosystem is anchored by its AirSense platform and myAir patient app, with cloud connectivity that has become central to both clinical outcomes and the commercial model. Manufacturing and distribution are global, which brings scale advantages but also exposure to freight, component costs and tariff policy — the last of these a recurring theme for US-listed medical device makers in recent years.

Portfolio reshaping is active. Alongside the MatrixCare divestment, the March-quarter earnings period brought news of an agreement to acquire Noctrix Health, adding a novel therapy in the adjacent restless legs syndrome space, and a CFO transition — evidence of a company adjusting its perimeter around what it calls its 2030 strategy: focusing on sleep health, breathing health and connected care delivered in the home.

Financial Position: Growth and Cash Generation Continue

ResMed's most recent reported quarter — the third quarter of fiscal 2026, ended 31 March 2026 and announced on 30 April 2026 — showed a business still compounding. Revenue rose 11% (8% in constant currency) to US$1.431 billion. GAAP gross margin expanded 290 basis points to 62.2%, helped by component cost improvements. GAAP diluted earnings per share came in at US$2.74, with non-GAAP EPS of US$2.86, up 21%. All figures are in US dollars as reported by the company.

Cash generation remained a hallmark: operating cash flow was US$554 million for the quarter, and the company returned US$262 million to shareholders through US$175 million of buybacks and US$87 million of dividends, while declaring a quarterly dividend of US$0.60 per share. For the first nine months of fiscal 2026, revenue reached US$4.19 billion with net income of US$1.14 billion.

The MatrixCare sale will add to the capital-return story if it completes as expected: ResMed has said it intends to use net proceeds of the US$490 million all-cash transaction to return capital to shareholders, including through an accelerated share repurchase program, and for general corporate purposes. MatrixCare generated about US$220 million of revenue and US$55 million of non-GAAP operating profit in fiscal 2026, so the divestment trades a modest earnings stream for balance-sheet flexibility and sharper focus.

Recent Announcements: MatrixCare Sale, Noctrix Deal and Analyst Moves

The most significant recent identified announcement came on 7 July 2026, when ResMed issued a press release confirming that on 30 June 2026 it entered a definitive agreement to sell MatrixCare to private equity firm Frazier Healthcare Partners for US$490 million in cash, subject to closing adjustments, with completion expected during the first quarter of ResMed's fiscal 2027. The company framed the sale as consistent with its 2030 strategy of concentrating on high-growth opportunities in sleep health, breathing health and connected home-based care.

That followed the 30 April 2026 third-quarter results package, which included the Noctrix Health acquisition announcement and a CFO transition. Early July also brought the analyst price target reductions noted above — RBC Capital, Wells Fargo and Jefferies among them — which, while not company announcements, form part of the information backdrop against which the shares have traded near 52-week lows. No new company announcement was identified on the morning of 13 July 2026 itself.

Sector and Macro Backdrop: A Defensive Sector That Isn't Defending

Healthcare is traditionally considered a defensive sector, yet ASX healthcare has repeatedly underperformed during 2026's bouts of volatility, and Monday was another example: the sector fell about 0.82% while energy gained 0.76% and the overall market slipped just 0.18%. When oil surges on geopolitical risk — Brent rose about 3.3% to around US$78.49 a barrel after the weekend's escalation between the US and Iran — market leadership rotates toward resources, and rate-sensitive growth sectors can suffer as inflation expectations firm.

For ResMed specifically, the macro overlay includes currency (a softer Australian dollar changes the CDI arithmetic relative to the US shares), US interest-rate expectations (which shape valuations for growth-oriented healthcare), and US healthcare policy and tariff settings. Layer on the GLP-1 debate — which has become a sector-wide theme touching everything from device makers to insurers — and healthcare's defensive reputation has offered ResMed holders little shelter this year. The stock's presence among Monday's biggest large-cap fallers underlines that dynamic.

Why the Move May Matter

A nearly 5% morning fall in one of the ASX's larger healthcare names matters mechanically — it drags on the index — but the more interesting significance is informational. ResMed is approaching its fiscal 2026 full-year results with its shares near 52-week lows, analyst targets being trimmed, and a fiercely contested narrative about its long-term demand pool. Weakness on no news in that setting suggests the market remains in "show me" mode: unwilling to extend the benefit of the doubt until the company demonstrates that GLP-1s are expanding rather than eroding its patient funnel, and that Philips' return is not degrading pricing or share.

The flip side is equally notable: the stock's derating has occurred while reported growth has remained double-digit and margins have expanded. If the upcoming results extend that pattern — and if the MatrixCare proceeds fund a meaningful buyback — the current gap between operating performance and share price could narrow. Which way it resolves is genuinely uncertain, and that uncertainty is precisely why the coming weeks matter.

Considerations That May Support the Case

Several verified fundamentals stand on ResMed's side of the ledger. Reported growth remains strong: revenue up 11% and non-GAAP EPS up 21% in the March quarter, with gross margin expanding 290 basis points to 62.2%. Cash generation is prodigious — US$554 million of operating cash flow in a single quarter — funding rising dividends and buybacks, soon potentially augmented by US$490 million of MatrixCare proceeds earmarked substantially for capital returns.

The structural demand argument also retains force: obstructive sleep apnoea remains massively underdiagnosed globally, and the company's own data — cited by its CEO — suggests GLP-1 users are more likely, not less, to commence PAP therapy. Portfolio moves such as the Noctrix acquisition add adjacent growth options, and some analyst commentary regards the stock as undervalued at current levels following the 2026 derating. Those valuation views are opinions; the reported numbers are not.

Risks and Uncertainties Investors May Weigh

The bear case cannot be dismissed. The long-run impact of GLP-1 medications on sleep apnoea prevalence and device demand is unknowable today; if weight-loss therapy meaningfully shrinks or delays the patient funnel, ResMed's growth assumptions would need revisiting — and management has already trimmed its growth outlook for parts of the respiratory business to mid-single digits, per market reporting. Competition is intensifying as Philips re-enters the US market, with potential consequences for share and price.

Execution risks attach to the CFO transition, the Noctrix integration and the MatrixCare separation, and the sale removes about US$220 million of annual revenue once completed. Currency, freight, component costs, tariffs and US reimbursement policy are perennial swing factors. For ASX holders specifically, CDI prices embed exchange-rate movement on top of the US share price. And as ever, Monday's figure was an intraday, 20-minute delayed snapshot — the close, and the US session that follows, may paint a different picture.

What Investors May Watch Next

The dominant near-term event is ResMed's fiscal 2026 fourth-quarter and full-year results, covering the year ended 30 June 2026. Investors may focus on device and masks growth rates, gross margin sustainability, commentary on GLP-1 patient-flow data, any observable impact from Philips' US return, and initial fiscal 2027 framing. Announcement of the results date, and any pre-result broker revisions, may themselves move the stock.

Beyond results: completion of the MatrixCare sale in the first quarter of fiscal 2027 and the size and timing of the flagged accelerated share repurchase; the naming and settling-in of a new CFO; progress on the Noctrix transaction; US tariff and reimbursement developments; and the currency, which shapes returns for Australian CDI holders independent of the underlying business.

ResMed (ASX: RMD): A Quality Franchise Trading Like a Question Mark

ResMed's fall of about 4.76% to $28.60 on the morning of 13 July 2026 came without any identified fresh announcement, on a day healthcare ranked among the ASX's biggest drags. On the available evidence, the move extends a year-long pattern: a company reporting double-digit growth, expanding margins and heavy cash returns, whose share price nonetheless sits near 52-week lows because the market cannot yet settle the GLP-1 and competition debates.

The next few months should be unusually informative. Full-year results will update the growth and margin picture; the MatrixCare completion would crystallise capital-return firepower; and another quarter of patient-flow data will feed the GLP-1 argument on both sides. Until those cards are turned over, volatility of the kind seen on Monday morning may remain a feature rather than an anomaly. Investors may treat single-session moves cautiously and weigh the accumulating evidence instead. This article is general information only and not financial advice.